Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000844681 | SCV000198831 | pathogenic | Hypertrophic cardiomyopathy | 2013-04-30 | criteria provided, single submitter | clinical testing | The Gln974X variant has been identified by our laboratory in 2 Caucasian individ uals with HCM (LMM unpublished data). This nonsense variant leads to a premature termination codon at position 974, which is predicted to lead to a truncated or absent protein. Truncating variants in MYBPC3 are a recognized pathogenic mecha nism for HCM. In summary, this variant meets our criteria to be classified as pa thogenic (http://pcpgm.partners.org/LMM) based upon the predicted impact to the protein. |
Gene |
RCV000414556 | SCV000490641 | pathogenic | not provided | 2015-07-09 | criteria provided, single submitter | clinical testing | The Q974X variant in the MYBPC3 gene has not been published as a pathogenic variant or as a benign polymorphism to our knowledge but has been reported as a pathogenic variant by two clinical laboratories (Landrum et al., 2014). Q974X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Other nonsense variants in the MYBPC3 gene have been reported in HGMD in association with HCM(Stenson P et al., 2014). Furthermore, the Q974X variant was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Therefore we interpret this variant as pathogenic. |
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, |
RCV005400705 | SCV000740365 | pathogenic | Cardiovascular phenotype | 2024-03-27 | criteria provided, single submitter | clinical testing | PVS1;PM2;PS4_supp;PP5 |
CHEO Genetics Diagnostic Laboratory, |
RCV001798469 | SCV002042183 | pathogenic | Cardiomyopathy | 2022-12-14 | criteria provided, single submitter | clinical testing |